Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and potentially commercializing gene therapies for severe inherited diseases affecting the central nervous system. The company was founded in 2019 and is headquartered at Pegasus Park in Dallas, Texas. Its technology approach centers on adeno-associated virus, or ...Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and potentially commercializing gene therapies for severe inherited diseases affecting the central nervous system. The company was founded in 2019 and is headquartered at Pegasus Park in Dallas, Texas. Its technology approach centers on adeno-associated virus, or AAV, vectors, which are engineered delivery vehicles intended to transport therapeutic genetic material into target cells. The objective is to address the underlying genetic cause of serious monogenic disorders rather than merely manage symptoms.
Taysha's most important disclosed program is TSHA-102, an investigational gene therapy for Rett syndrome, a rare neurodevelopmental disorder commonly associated with mutations in the MECP2 gene. Rett syndrome is characterized by developmental regression, impaired communication, motor dysfunction, and other neurological complications. The program is intended to restore or supplement functional genetic activity through an AAV-based approach. Because TSHA-102 remains investigational, its safety, efficacy, durability, dosing, and regulatory prospects depend on clinical-trial results and review by health authorities.
The company has also disclosed programs and research activities involving disorders such as giant axonal neuropathy, CLN1 disease, SLC13A5 deficiency, and GM2 gangliosidosis. Earlier pipeline descriptions included TSHA-120, TSHA-121, TSHA-118, TSHA-105, and TSHA-101. However, public reporting indicates that Taysha has narrowed its portfolio and that its current investment thesis is increasingly concentrated on TSHA-102. Pipeline status can change as clinical, regulatory, financing, and strategic decisions evolve.
Taysha was formed with a close relationship to The University of Texas Southwestern Medical Center, supporting access to scientific expertise, disease biology, vector technology, and translational research. The company has also built capabilities related to gene-therapy development and manufacturing, although manufacturing scale, quality control, supply-chain execution, and cost of goods remain important considerations for any potential commercial product. AAV manufacturing can require specialized facilities, expensive raw materials, rigorous testing, and complex release procedures. Commercial costs may also be affected by patient identification, treatment-center infrastructure, logistics, and long-term follow-up requirements.
Sean P. Nolan serves as chairman of the board and chief executive officer; he became CEO in 2022 after previously serving in senior biopharmaceutical leadership roles. The supplied company data lists approximately 99 full-time employees, placing Taysha in the 0-100 employee category. As a development-stage biotechnology company, Taysha has historically operated with significant research, development, regulatory, clinical, and administrative expenses and has not generated material product revenue. The supplied trailing data shows negative operating margins, negative net income, and negative free cash flow, alongside a strong current ratio and substantial cash relative to near-term obligations. Consequently, liquidity, cash burn, financing requirements, dilution risk, clinical results, regulatory milestones, and partnership opportunities are central considerations for shareholders. Taysha's stated long-term aspiration is to develop transformative treatments for patients with severe genetic neurological diseases, but commercial success depends on demonstrating meaningful benefit, obtaining regulatory approval, manufacturing reliably, and securing reimbursement.
Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal
InteranualYoY significa Year-over-Year (interanual). Compara el último valor anual con el valor anual anterior para mostrar la fortaleza de la tendencia a largo plazo.
TrimestralQoQ significa Quarter-over-Quarter (intertrimestral). Compara el último trimestre con el trimestre inmediatamente anterior para mostrar cambios de impulso a corto plazo.
IngresosEl dinero total que entró por la puerta principal al vender cosas, antes de pagar una sola factura. Piensa en esto como el gran total de cada compra con tarjeta de los clientes. (YoY compara el rendimiento de este año con el del año pasado, mientras que QoQ compara los tres meses actuales con los tres anteriores).
$9.8M
+17.3%
—
Beneficio netoEl resultado final absoluto. Si la empresa pagara a cada proveedor, empleado, banquero y recaudador de impuestos, este es el dinero real que queda en su bolsillo al final del día.
$-109.0M
-22.1%
-10.0%
Margen brutoEl margen básico. Si venden unas zapatillas de 100 dólares, este porcentaje indica cuánto de ese precio es ganancia justo después de pagar el caucho y los cordones, pero antes de pagar el alquiler de la tienda o los anuncios de televisión.
+100.0%
0.0%
—
Margen operativoLa puntuación de eficiencia del 'trabajo diario'. De cada dólar que gasta un cliente, esto muestra cuántos centavos mantiene la empresa después de fabricar el producto Y pagar todos los gastos generales corporativos (como salarios, marketing y mantener las luces encendidas).
-1130.6%
-3.0%
—
Margen netoEl porcentaje final que se lleva a casa. Cuando se eliminan todos los costos concebibles, impuestos y pagos de intereses, este es el número exacto de centavos que la empresa realmente se queda de cada dólar en ventas.
-1115.3%
-4.1%
—
Flujo de caja libreEl santo grial del efectivo corporativo. Es el dinero físico gastable que queda después de que el negocio paga sus operaciones diarias Y compra las actualizaciones grandes y costosas (como nuevas fábricas o servidores) que necesita para sobrevivir. Este es el dinero 'libre' que pueden usar para pagar dividendos o recomprar acciones.
$-93.8M
-15.0%
+7.9%
Margen FCFLa tasa definitiva de conversión de efectivo. Muestra qué tan buena es la empresa para convertir ventas regulares directamente en efectivo frío, duro y gastable. Un porcentaje alto significa que el negocio es una auténtica máquina de imprimir dinero.
-960.1%
+2.0%
—
Deuda/PatrimonioEl indicador de riesgo financiero. Compara cuánto del imperio de la empresa se construyó con dinero prestado (préstamos) frente al dinero propio de los propietarios (accionistas). Un número alto significa que están muy apalancados y juegan un juego más arriesgado; un número bajo significa que juegan a lo seguro.
7.4%
-91.7%
+71.1%
Ratio corrienteLa verificación de supervivencia de 12 meses. Simplemente compara el efectivo que tienen ahora mismo (más cosas que pueden convertirse rápidamente en efectivo) con las facturas inmediatas que absolutamente deben pagar este año. Una puntuación superior a 1 significa que tienen suficiente en la billetera para cubrir las próximas facturas sin entrar en pánico.
12.23x
+125.6%
+26.5%
Activos totalesEl tamaño absoluto del imperio de la empresa. Agrupa absolutamente todo lo valioso que poseen, desde el efectivo en la caja registradora y el inventario en el almacén, hasta las patentes de software en la bóveda y las fábricas en el suelo.
Operator: Hello, and welcome to the Taysha Gene Therapies Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. It is now my pleasure to introduce Vice President of Corporate Communications and Investor Relations, Hayleigh Collins.
Hayleigh Collins: Thank you. Good afternoon, and welcome to Taysha's second quarter 2026 financial results and corporate update conference call. Earlier today, Taysha issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of this press release is available on the company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Taysha's Chief Executive Officer, Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks. On today's call, we will be making forward-looking statements, including statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, to positively impact quality of life and alter the course of disease in the patients we seek to treat. Our research, development, and regulatory plans for our product candidates, including the timing of initiating additional trials, reporting data from our clinical trials, and making regulatory submissions, timing or outcomes of communications with the FDA on the regulatory pathway for TSHA-102, the potential for product candidate to receive regulatory approval from the FDA or equivalent foreign regulatory agencies. Our ability to realize the benefits of breakthrough therapy designations for TSHA-102, our ability to drive long-term value for stockholders, and the market opportunity for our programs. This call may also contain forward-looking statements relating to Taysha's growth, forecasted cash runway, and future operating results, discovery and development of product candidates, strategic alliances and intellectual property, as well as matters that are not historical facts or information. Various risks may cause Taysha's actual results to differ materially from those stated or implied in such forward-looking statements. For a list and description of the risks and uncertainties that we face, please see the reports we filed with the SEC, including our annual report on Form 10-K for the full year ended December 31, 2025, that we filed on March 19, 2026. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, August 11, 2026. Taysha undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities laws. With that, I would now like to turn the call over to our CEO, …
